GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Azitra Inc (AMEX:AZTR) » Definitions » Earnings per Share (Diluted)

AZTR (Azitra) Earnings per Share (Diluted) : $-22.45 (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Azitra Earnings per Share (Diluted)?

Azitra's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.17. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-22.45.

Azitra's EPS (Basic) for the three months ended in Sep. 2024 was $-0.17. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-22.45.

Azitra's EPS without NRI for the three months ended in Sep. 2024 was $-0.86. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-23.18.


Azitra Earnings per Share (Diluted) Historical Data

The historical data trend for Azitra's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azitra Earnings per Share (Diluted) Chart

Azitra Annual Data
Trend Dec21 Dec22 Dec23
Earnings per Share (Diluted)
-29.06 -33.38 -54.90

Azitra Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.82 -15.04 -4.50 -2.74 -0.17

Competitive Comparison of Azitra's Earnings per Share (Diluted)

For the Biotechnology subindustry, Azitra's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Azitra's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Azitra's PE Ratio distribution charts can be found below:

* The bar in red indicates where Azitra's PE Ratio falls into.



Azitra Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Azitra's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-11.284-1.355)/0.231
=-54.71

Azitra's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2024 is calculated as

Diluted Earnings Per Share (Q: Sep. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-1.009-0)/5.814
=-0.17

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Azitra  (AMEX:AZTR) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Azitra Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Azitra's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Azitra Business Description

Industry
Traded in Other Exchanges
N/A
Address
21 Business Park Drive, Branford, CT, USA, 06405
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.
Executives
Norm Staskey officer: Chief Financial Officer 21 BUSINESS PARK DRIVE, BRANFORD CT 06405
Francisco D. Salva director, officer: President and CEO 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Travis Whitfill director, officer: Chief Operating Officer C/O IN8BIO,INC., 79 MADISON AVENUE, NEW YORK NY 10016
Fletcher Aaron G.l. 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Andrew Mcclary director 21 BUSINESS PARK DRIVE, BRANFORD CT 06405
Aktiengesellschaft Bayer 10 percent owner BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368
Bios Azitra Co-invest I, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bayer Us Holding Lp 10 percent owner 100 BAYER BOULEVARD, WHIPPANY NJ 07981
Bayer Healthcare Llc 10 percent owner
Bios Equity Partners Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107